Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease
Journal of Gastroenterology · 19.06.2026
DOI: 10.1007/s00535-026-02466-6 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Gastroenterology, online erschienen am 19.06.2026. Verfasst von Rong Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
- Department of Gastroenterology, The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350004, China. yechengqian123@163.com.
Zitieren
APA
Peng, R., Lin, L., & Ye, C. (2026). Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02466-6
Vancouver
Peng R, Lin L, Ye C. Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02466-6
BibTeX
@article{Peng2026,
author = {Peng, Rong and Lin, Lingzhen and Ye, Chengqian},
title = {Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease},
journal = {Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s00535-026-02466-6}
}
EUVIMED